Investigation of Corticosteroid Excretion Patterns in Healthy Volunteers for Enhanced Anti-Doping Detection

The primary objective of this study is to evaluate the **excretion** patterns of **corticosteroids** in healthy volunteers to enhance their detection in anti-doping controls. This is clinically relevant as it aims to improve the accuracy and reliability of anti-doping tests, which are crucial for maintaining fairness and integrity in competitive sports. No secondary objectives are specified for this study.

The clinical trial involves **healthy volunteers** as the study population, encompassing both male and female participants. The age range of the participants is categorized as adults, specifically between 18 to 65 years. The trial does not include a vulnerable population. The sponsor has not provided information regarding the total number of participants. Participants were selected based on their general health status, ensuring they are free from any significant medical conditions. Lifestyle considerations such as diet, physical activity, and habits were not specified in the available data. Key inclusion or exclusion criteria were not detailed by the sponsor.

The clinical trial is designed to evaluate the **excretion** of corticosteroids in healthy volunteers to enhance detection in anti-doping controls. This study is a Phase 3 trial, which is expected to commence recruitment on February 18, 2024, and conclude by August 18, 2024. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. Participants will be randomly assigned to either the treatment group or the control group, with neither the participants nor the investigators aware of the group assignments, thus maintaining the integrity of the blinding process.

The sequence of study visits begins with an inclusion visit, where potential participants undergo a screening process to determine eligibility based on predefined criteria. Following successful screening, participants will be enrolled in the study and will attend a series of follow-up visits at specified intervals. These visits are crucial for monitoring the participants' health status, collecting data on corticosteroid excretion, and ensuring adherence to the study protocol. The end-of-study visit marks the conclusion of the participant's involvement, where final assessments are conducted, and data is collected for analysis.

The expected duration of participant involvement in the trial is approximately six months, aligning with the overall trial timeline. Participants may be subject to early termination from the study if they experience adverse events, fail to comply with the study protocol, or withdraw consent. The trial's design and procedures are structured to uphold ethical standards and ensure the safety and well-being of all participants throughout the study duration.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is available from the provided data. Consequently, a detailed description of the experimental treatment cannot be provided.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Therefore, a description of these elements is not possible based on the current data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. As such, these aspects cannot be detailed in this description.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to begin recruitment on February 18, 2024, with an estimated end date of August 18, 2024. The efficacy assessment will be conducted through a series of planned evaluations, although specific parameters or endpoints for efficacy evaluation are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis, adhering to the rigorous standards expected in a Phase 3 clinical trial. The focus will be on obtaining reliable and valid results to determine the efficacy of the intervention under investigation.